If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director Shareholding

2 Mar 2005 14:05

GW Pharmaceuticals PLC02 March 2005 For Immediate Release 2 March 2005 GW Pharmaceuticals plc ('the Company') Share Options The following Directors of the Company have been granted share options on 2March 2005, as detailed below: Director No. of shares over which Total no. of shares over options granted which options held Dr Geoffrey 302,344 1,083,924Guy Justin 239,063 1,491,167Gover David Kirk 217,969 1,773,747 Dr Brian 98,438 678,230Whittle David Mace 45,000 251,620 Hans 45,000 119,120Schram Peter 45,000 179,120Mountford The options to acquire ordinary shares of 0.1p in the Company have been grantedat an exercise price of 128p and are exercisable from 2 March 2008 to 2 March2015 and have been granted as part of the Directors' remuneration review carriedout at the end of 2004. For further information please contact Jonathan Laughton, Company Secretary &Financial Controller, GW Pharmaceuticals plc on +44 (0) 1980 557 000. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Sep 20152:37 pmRNSBlock Listing Application
17th Aug 20159:14 amRNSBlocklisting Interim Review
6th Aug 201512:28 pmRNSThird Quarter 2015 Financial Results
6th Aug 201511:45 amRNSFDA Fast Track and EMA Orphan Designations for CBD
23rd Jul 201512:00 pmRNSNotice of Results
16th Jul 20154:15 pmRNSAppointment of Director
16th Jul 201510:40 amRNSHolding(s) in Company
9th Jul 20154:57 pmRNSHolding(s) in Company
9th Jul 20154:24 pmRNSHolding(s) in Company
7th Jul 20153:23 pmRNSHolding(s) in Company
30th Jun 20157:00 amRNSDirector/PDMR Shareholding
24th Jun 20155:56 pmRNSDirector/PDMR Shareholding
12th Jun 20155:39 pmRNSDirector/PDMR Shareholding
11th Jun 201512:00 pmRNSSecond Ph3 Pivotal Study of Epidiolex in LGS
1st Jun 201510:19 amRNSBlock Listing Application
1st Jun 20157:54 amRNSHolding(s) in Company
1st Jun 20157:53 amRNSHolding(s) in Company
29th May 201511:13 amRNSHolding(s) in Company
19th May 201512:00 pmRNSAppoints US Executive; Relocates CEO to US
15th May 20155:43 pmRNSPurchase of Additional American Depositary Shares
11th May 20153:00 pmRNSPresenting at BAML 2015 Healthcare Conference
11th May 201512:00 pmRNSHalf Yearly Report
11th May 201512:00 pmRNSInitiates Ph3 Pivotal Study of Epidiolex in LGS
11th May 201511:45 amRNSHolding(s) in Company
11th May 201511:45 amRNSHolding(s) in Company
8th May 20154:22 pmRNSHolding(s) in Company
6th May 201512:00 pmRNSNotice of Results
6th May 201512:00 pmRNSInitiates Phase 2 Trial of CBDV in Epilepsy
6th May 20157:01 amRNSClosing of U.S. Public Offering of ADSs
1st May 20153:28 pmRNSHolding(s) in Company
1st May 20157:30 amRNSHolding(s) in Company
29th Apr 20157:00 amRNSPricing of U.S. Public Offering of ADSs
28th Apr 20157:00 amRNSProposed Public Offering of ADSs
27th Apr 201512:00 pmRNSUS Patent Allowance for Use of Cannabidivarin
24th Apr 201512:00 pmRNSOrphan Drug Designation for CBD in NHIE
23rd Apr 20157:00 amRNSNew Physician Reports of Epidiolex Treatment
21st Apr 201512:00 pmRNSStarts 2nd Ph 3 Epidiolex Trial in Dravet Syndrome
14th Apr 20157:00 amRNSNew Epidiolex Data Released by AAN
1st Apr 20152:03 pmRNSHolding(s) in Company
31st Mar 201512:00 pmRNSStarts Ph 3 Trial for Epidiolex in Dravet Syndrome
17th Mar 20155:18 pmRNSHolding(s) in Company
17th Mar 20155:15 pmRNSHolding(s) in Company
25th Feb 201512:00 pmRNSPresenting at Upcoming Investor Conferences
17th Feb 20153:25 pmRNSBlocklisting Interim Review
16th Feb 20153:52 pmRNSHolding(s) in Company
16th Feb 20153:48 pmRNSHolding(s) in Company
9th Feb 20155:31 pmRNSDirector/PDMR Shareholding
5th Feb 20152:25 pmRNSResult of AGM
5th Feb 201512:00 pmRNSPresents at Leerink Global Healthcare Conference
4th Feb 201512:01 pmRNS1st Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.